NU7441 (KU-57788): Selective ATP-Competitive DNA-PK Inhibitor for Oncology and DNA Repair Research

Executive Summary: NU7441 (KU-57788) is a nanomolar-potent and highly selective DNA-dependent protein kinase (DNA-PK) inhibitor that acts via ATP-competitive mechanisms, with an IC₅₀ of 13–14 nM and a Ki of 0.65 nM under in vitro kinase assay conditions (APExBIO). At concentrations up to 100 μM, NU7441 does not significantly inhibit related kinases ATM or ATR, while its activity against mTOR and PI3K is much weaker (IC₅₀ = 1.7 μM and 5 μM, respectively) (Miao et al., 2023). This compound sensitizes multiple cancer cell lines to DNA-damaging agents, enhances cytotoxicity, and induces cell cycle arrest in G1 phase (internal resource). NU7441 is insoluble in water and ethanol but dissolves in DMSO at ≥4.13 mg/mL; it must be stored at -20°C for stability. In vivo, co-administration with etoposide doubles tumor growth delay versus etoposide alone in SW620 xenograft models (Miao et al., 2023).

Biological Rationale

DNA double-strand breaks (DSBs) are highly cytotoxic lesions whose repair is essential for genomic stability. DNA-PK, a serine/threonine kinase, orchestrates non-homologous end joining (NHEJ), the primary DSB repair pathway in mammalian cells (Miao et al., 2023). Overexpression or hyperactivity of DNA-PK is frequently observed in cancer cells, contributing to radio- and chemoresistance. Inhibitors like NU7441 enable precise interrogation of DNA-PK-mediated repair, cell cycle progression, and downstream immune modulation. Targeted DNA-PK inhibition is a rational strategy for sensitizing tumor cells to genotoxic agents and for dissecting the DNA damage response (DDR) pathway in both basic and translational research contexts.

Mechanism of Action of NU7441 (KU-57788)

NU7441 selectively binds to the ATP-binding site of DNA-PKcs, competitively inhibiting its kinase activity (IC₅₀ = 13–14 nM; Ki = 0.65 nM) (Miao et al., 2023). This inhibition blocks autophosphorylation and downstream phosphorylation of NHEJ substrates, preventing efficient DSB repair. NU7441 has negligible activity against ATM and ATR kinases at concentrations up to 100 μM, supporting its use in mechanistic studies without major off-target confounders. At much higher concentrations, weak inhibition of mTOR (IC₅₀ = 1.7 μM) and PI3K (IC₅₀ = 5 μM) may occur, but these values remain far above those required for DNA-PK inhibition. By impeding NHEJ, NU7441 increases cellular sensitivity to radiation and topoisomerase II poisons (e.g., etoposide), leading to apoptotic cell death and cell cycle arrest predominantly in the G1 phase (internal resource).

Evidence & Benchmarks

• NU7441 inhibits DNA-PK with an IC₅₀ of 13–14 nM and a Ki of 0.65 nM in cell-free kinase assays (Miao et al., 2023).
• It does not significantly inhibit ATM or ATR even at 100 μM, confirming high selectivity (Miao et al., 2023).
• mTOR and PI3K are inhibited only at micromolar concentrations (IC₅₀ = 1.7 μM and 5 μM, respectively), indicating minimal off-target effects under standard conditions (Miao et al., 2023).
• In HeLa, LoVo, and SW620 cell lines, NU7441 sensitizes cells to etoposide and ionizing radiation, enhancing cytotoxicity and causing G1 phase arrest (Miao et al., 2023).
• In vivo, 10 mg/kg intraperitoneal NU7441 with etoposide phosphate doubles tumor growth delay in SW620 xenograft mice compared to etoposide alone (Miao et al., 2023).
• NU7441 is insoluble in water and ethanol but soluble in DMSO at concentrations ≥4.13 mg/mL; recommended storage is at -20°C (APExBIO).
• NU7441 has been used to dissect the miR-375/PRKDC/PD-L1 axis in tumor immune evasion studies (Miao et al., 2023).

This article extends the scope of 'NU7441 (KU-57788): Selective ATP-Competitive DNA-PK Inhib...' by providing current evidence on selectivity and in vivo efficacy benchmarks. For practical assay and protocol troubleshooting, see 'NU7441 (KU-57788): Scenario-Driven Solutions for DNA-PK I...', which this article complements with updated mechanistic insights and specificity data.

Applications, Limits & Misconceptions

NU7441 (KU-57788) is widely applied in:

• DNA repair pathway dissection (especially NHEJ vs. HR balance).
• Oncology research, including radiosensitization and chemosensitization studies.
• Cell cycle arrest and checkpoint integrity assays.
• Interrogation of the DNA damage response and immune evasion pathways (e.g., miR-375/PRKDC/PD-L1 axis).

Common Pitfalls or Misconceptions

• NU7441 is not effective in inhibiting ATM or ATR at standard concentrations; it cannot substitute for ATM/ATR inhibitors.
• Effective in vitro concentrations are in the nanomolar range; micromolar dosing risks off-target mTOR/PI3K inhibition.
• NU7441 is insoluble in water and ethanol; improper solvent choice can lead to precipitation and unreliable results (APExBIO).
• Long-term storage of dissolved NU7441 is not recommended due to compound instability in solution.
• NU7441 cannot reverse established DNA damage; it is preventive, not reparative.

Workflow Integration & Parameters

NU7441 (KU-57788) is supplied by APExBIO as SKU A8315 (NU7441 product page). For cell-based assays, stock solutions (≥10 mM) should be prepared in DMSO and aliquoted to minimize freeze-thaw cycles. Typical working concentrations range from 10–500 nM for DNA-PK-specific effects; higher doses should be justified by experimental controls for mTOR/PI3K off-targets. Storage at -20°C and protection from light are recommended. In combination assays, NU7441 should be added prior to or simultaneously with DNA-damaging agents. For in vivo studies, 10 mg/kg intraperitoneal injection has shown robust efficacy in mouse xenograft models (Miao et al., 2023).

For expanded technical advice and troubleshooting, 'Optimizing DNA Damage Response Assays with NU7441 (KU-577...' provides scenario-driven optimization steps; this article updates those recommendations with the latest selectivity and in vivo efficacy data.

Conclusion & Outlook

NU7441 (KU-57788) remains a benchmark tool compound for dissecting DNA-PK function in DNA repair, oncology, and immuno-oncology research. Its selectivity profile, nanomolar potency, and proven utility in both in vitro and in vivo workflows ensure continued relevance for the study of DDR, tumor radiosensitization, and immune escape. As new mechanistic links—such as the miR-375/PRKDC/PD-L1 axis—continue to emerge, NU7441 will facilitate discovery and translational innovation. For stable supply and technical support, APExBIO provides validated product batches and up-to-date protocols (see A8315 kit).